Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473687 | 1.00 | BACE1 (0.50) | BACE1KMT2AHTTDYRK1ADYRK1B | |
| SCHEMBL29862595 | 0.80 | SMN1; SMN2 (0.38) | BACE1KMT2AHTTDYRK1ADYRK1B | |
| SCHEMBL23360456 | 0.80 | SMN1; SMN2 (0.38) | BACE1KMT2AHTTDYRK1ADYRK1B | |
| SCHEMBL5355204 | 0.79 | PLAU (0.47) | BACE1KMT2AHTTMAP4K4ROCK1 | |
| SCHEMBL4923752 | 0.79 | SMN1; SMN2 (0.40) | BACE1KMT2AHTTDYRK1ADYRK1B | |
| SCHEMBL12687394 | 0.76 | DYRK1B (0.38) | KMT2AHTTDYRK1ADYRK1BCHEK1 | |
| SCHEMBL31752133 | 0.76 | SMN1; SMN2 (0.46) | HTTDYRK1AAURKASMN1; SMN2ALDH1A1 | |
| SCHEMBL5489275 | 0.73 | FGFR1 (0.46) | KMT2AHTTDYRK1ADYRK1BCHEK1 | |
| SCHEMBL13226821 | 0.73 | SMN1; SMN2 (0.40) | HTTDYRK1ADYRK1BCHEK1AURKA | |
| SCHEMBL1500697 | 0.73 | SMN1; SMN2 (0.48) | KMT2AHTTDYRK1ADYRK1BCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| EP-3638672-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| CN-110753692-A | Chemical compounds as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2018229629-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | WO | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-5843967-A | 6-membered nitrogen-containing heteroaryl-oxazolidinones | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| US-5627181-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-06 | — | — | US | disclosed |
| CN-1119647-A | 6-membered nitrogen-containing heteroaryl-oxazolidinones | BAYER AG (DE) | 1996-04-03 | — | — | CN | disclosed |
| EP-0694543-A1 | 6-membered N-heteroaryloxazolidinones | BAYER AG (DE) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | HPGDS, PTGS1, PTGIS | BACE1 4470/4885KMT2A 3090/4885HTT 580/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | BACE1 287/4885KMT2A 4380/4885HTT 2715/4885 |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | HPGDS, PTGS1, PTGIS | BACE1 4430/4885KMT2A 3123/4885HTT 655/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | BACE1 3008/4885KMT2A 2000/4885HTT 1868/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | BACE1 3008/4885KMT2A 2000/4885HTT 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.